Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Imatinib mesylate, 400 mg/d, is considered standard therapy for managing patients with chronic myeloid leukemia (CML) in chronic phase, yielding high rates of cytogenetic responses that translate into favorable long-term outcomes. However, some patients do not achieve adequate levels of response, lose a previously acquired response, or are forced to discontinue imatinib therapy because of safety reasons. To avoid these outcomes, several approaches are being tested in the frontline setting, including the use of higher imatinib doses or second-generation tyrosine kinase inhibitors such as nilotinib or dasatinib, the latter of which is approved only for managing patients who have imatinib therapy failure. Newer multikinase inhibitors active against multiple ABL1 mutations are also under development for patients in any CML phase who have therapy failure on sequential imatinib and a second-generation tyrosine kinase inhibitor or carry the highly resistant T315I mutation and are not candidates for allogeneic stem cell transplantation. Some of these approaches are expected to improve the outcomes of patients with CML.
Quintás-Cardama
Alfonso
A
Department of Leukemia, University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jcortes@mdanderson.org
Cortes
Jorge
J
D001549:Benzamides; D000069439:Dasatinib; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib; D000069439:Dasatinib
Leukemia. 2009 Mar;23(3):477-85
19039322
Cancer. 2008 Feb 15;112(4):837-45
18085610
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Cancer Cell. 2005 Feb;7(2):129-41
15710326
J Clin Oncol. 2009 Jan 20;27(3):469-71
19075254
Blood. 2009 Mar 5;113(10):2154-60
19060245
Cancer. 2007 Jan 15;109(2):248-55
17154172
Blood. 2007 Apr 15;109(8):3496-9
17192396
Blood. 2003 Jul 1;102(1):83-6
12637317
Clin Cancer Res. 2005 May 1;11(9):3425-32
15867244
N Engl J Med. 2003 Mar 13;348(11):994-1004
12637609
Blood. 2008 Nov 15;112(10):3965-73
18768781
Cancer Res. 2005 Jun 1;65(11):4500-5
15930265
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
N Engl J Med. 2006 Jun 15;354(24):2542-51
16775235
Science. 2004 Jul 16;305(5682):399-401
15256671
Blood. 2004 Apr 15;103(8):2873-8
15070658
N Engl J Med. 2007 Oct 11;357(15):1557; author reply 1557-8
17933034
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20
7682708
Blood. 2007 Jan 15;109(2):497-9
16990591
Nat Rev Cancer. 2007 May;7(5):345-56
17457302
J Clin Oncol. 2008 Jul 10;26(20):3358-63
18519952
Cancer Control. 2009 Apr;16(2):122-31
19337198
Leukemia. 2003 Dec;17(12):2401-9
14523461
Leukemia. 2009 Aug;23(8):1446-54
19322212
Blood. 2008 Apr 15;111(8):4022-8
18256322
N Engl J Med. 2001 Apr 5;344(14):1038-42
11287973
Blood. 2007 Nov 15;110(10):3540-6
17715389
N Engl J Med. 2003 Oct 9;349(15):1423-32
14534335
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234